Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Mining ancient proteins for next-generation drugs

Nature Biotechnology volume 35, pages 28–29 (2017)Cite this article

Subjects

Predicting the evolutionary ancestors of a protein drug provides a strategy for optimizing its pharmaceutical properties.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Protein engineering technologies.

Debbie Maizels / Springer Nature

References

  1. Leader, B., Baca, Q.J. & Golan, D.E. Nat. Rev. Drug Discov. 7, 21–39 (2008).

    Article  CAS  Google Scholar 

  2. Carter, P.J. Exp. Cell Res. 317, 1261–1269 (2011).

    Article  CAS  Google Scholar 

  3. Zakas, P.M. et al. Nat. Biotechnol. 35, 35–37 (2017).

    Article  CAS  Google Scholar 

  4. Merkl, R. & Sterner, R. Biol. Chem. 397, 1–21 (2016).

    Article  CAS  Google Scholar 

  5. Morfini, M. & Zanon, E. Expert Opin. Emerg. Drugs 21, 301–313 (2016).

    Article  CAS  Google Scholar 

  6. Griswold, K.E. & Bailey-Kellogg, C. Curr. Opin. Struct. Biol. 39, 79–88 (2016).

    Article  CAS  Google Scholar 

  7. Packer, M.S. & Liu, D.R. Nat. Rev. Genet. 16, 379–394 (2015).

    Article  CAS  Google Scholar 

  8. Arruda, V.R. & Samelson-Jones, B.J. J. Thromb. Haemost. 14, 1121–1134 (2016).

    Article  CAS  Google Scholar 

  9. Tarantino, M.D., Cuker, A., Hardesty, B., Roberts, J.C. & Sholzberg, M. Haemophilia http://dx.doi.org/10.1111/hae.13040 (2016).

  10. Gomperts, E. Expert Rev. Hematol. 8, 427–432 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert A. Lazarus is in the Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California, USA, and,

    Robert A Lazarus

  2. Friedrich Scheiflinger is at Research EU, Shire, Vienna, Austria.,

    Friedrich Scheiflinger

Authors
  1. Robert A Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedrich Scheiflinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Robert A Lazarus or Friedrich Scheiflinger.

Ethics declarations

Competing interests

R.A.L. is an employee of Genentech, Inc., which is developing drugs in the area of hematology. F.S. is an employee of Shire, which is developing drugs in the area of hematology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lazarus, R., Scheiflinger, F. Mining ancient proteins for next-generation drugs. Nat Biotechnol 35, 28–29 (2017). https://doi.org/10.1038/nbt.3762

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3762

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing